Roche Jumps After Weight-Loss Pill Shows Promise in Study (2)

Roche Holding AG shares jumped after its experimental weight loss pill showed meaningful weight reduction in an early stage study among obesity patients, setting up the Swiss drugmaker as a challenger in the field.

Patients who took the oral medication, CT-996, once a day for four weeks lost on average more than 7% of their starting weight, compared with a little over 1% weight loss in patients who received a placebo, the Swiss drugmaker said in a statement Wednesday.

Roche rose as much as 7.4% in early trading, the most since March 2020. The stock is up about 13% since ...